Comparison of symptom severity in natural and experimentally induced colds

American Journal of Rhinology

Volumn 10, Issue 3, 1996, Pages 167-172

  Turner, Ronald B ^a   Witek Jr , Theodore J ^a   Riker, Donald K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006090364     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/105065896781794888     Document Type: Article

References (18)

1. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. Arch Intern Med 101:267-278, 1958.
2. Gwaltney JM Jr. Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 166:776-782, 1992.
3. Hayden FG, Gwaltney JM Jr. Prophylactic activity of intranasal enviroxime against experimentally-induced rhinovirus type 39 infection. Antimicrob Agents Chemother 21:892-897, 1982.
4. Hayden FG, Gwaltney JM Jr. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis 148: 543-550, 1983.
5. Gwaltney JM Jr., Hendley O, Hayden FG, et al. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. Prog Med Virol 39:256263, 1992.
6. Connell JT. Rhinometry: Measurement of nasal patency. Ann Allergy 49:179-185, 1982.
7. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect 111:143-156, 1993.
8. Rao SS, Hendley JO, Hayden FG, Gwaltney JM Jr. Symptom expression in natural and experimental rhinovirus colds. Am J Rhinol 9:49-52, 1995.
9. Meschievitz CK, Schultz SB, Dick EC. A model for obtaining predictable natural transmission of rhinoviruses in human volunteers. J Infect Dis 150:195-201, 1984.
10. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 314:65-70, 1986.
11. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. N Engl J Med 314:71-75, 1986.
12. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-a2b for seasonal prophylaxis of respiratory infection. J Infect Dis 154:128-133, 1986.
13. Samo TC, Greenberg SB, Couch RB, et al. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 148:535-542, 1983.
14. Levandowski RA, Pachucki CT, Rubenis M, Jackson GG. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother. 22:1004-1007, 1982.
15. Miller FD, Monto AS, DeLong DC, et al. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother 27:102-106, 1985.
16. Gaffey MJ, Hayden FG, Boyd JC, Gwaltney JM Jr. Ipratropium bromide treatment of experimental rhinovirus infection. Antimicrob Agents Chemother 32:1644-1647, 1988.
17. Duckhorn R, Grossman J, Posner M, Zinny M, Tinkleman D. A double-blind, placebo-controlled study of the safety and efficacy of ipratropium bromide nasal spray versus placebo in patients with the common cold. J Allergy Clin Immunol 90:1076-1082, 1992.
18. Gwaltney JM Jr., Park J, Paul RA, Turner RB, et al. A randomized controlled trial of clemastine fumarate in experimental rhinovirus colds. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, Am Soc Microbiol 1994.